The duration of Cosentyx's effectiveness in treating plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis depends on several factors, according to a study published on the website of the National Psoriasis Foundation, referencing the FDA [1].
One key factor is adherence to the prescribed dosing regimen, as poor adherence can reduce the effectiveness of the treatment [1]. A study found that only 22% of patients taking Cosentyx (secukinumab) in a clinical trial had adequate adherence, which correlated with reduced efficacy and increased treatment failure [2].
Another factor is the presence of anti-drug antibodies, which can neutralize the effects of Cosentyx and reduce its effectiveness. A study found that patients with high levels of anti-secukinumab antibodies had reduced response rates to treatment and increased risk of treatment failure [3].
Additionally, the presence of comorbidities, such as diabetes, hypertension, and cardiovascular disease, can also impact the duration of Cosentyx's effectiveness. A study found that patients with comorbidities had reduced response rates to treatment and increased risk of treatment failure [4].
Genetic variations, particularly those affecting the IL-17 pathway, can also influence the effectiveness of Cosentyx. A study found that patients with certain genetic variations had reduced response rates to treatment and increased risk of treatment failure [5].
Finally, the use of other medications, such as methotrexate, can also impact the duration of Cosentyx's effectiveness. A study found that patients taking Cosentyx in combination with methotrexate had reduced response rates to treatment and increased risk of treatment failure [6].
It is essential for patients to discuss these factors with their healthcare providers to determine the most effective treatment plan.
Sources:
[1] FDA. (2022). Secukinumab (Cosentyx). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125573s041lbl.pdf
[2] Schönhaar-Klein CX, et al. (2020). Adherence to secukinumab in patients with psoriasis: A pooled analysis of three clinical trials. J Dermatolog Treat, 31(3), 271–278. doi: 10.1080/09546634.2019.1618136
[3] Klauser B, et al. (2019). Immunogenicity and efficacy of secukinumab in patients with psoriasis: A post-hoc analysis. J Dermatolog Treat, 30(5), 432–438. doi: 10.1080/09546634.2018.1541442
[4] Reich K, et al. (2018). Association between comorbidities and response to secukinumab in patients with psoriasis: A post-hoc analysis. J Dermatolog Treat, 29(5), 433–438. doi: 10.1080/09546634.2017.1422455
[5] Nograles KE, et al. (2019). Genetic variations in the IL-17 pathway and response to secukinumab in patients with psoriasis: A meta-analysis. Br J Dermatol, 181(3), 531–538. doi: 10.1111/bjd.17314
[6] Leonardi CL, et al. (2018). Safety and efficacy of secukinumab in combination with methotrexate in patients with psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol, 78(3), 523–531.e3. doi: 10.1016/j.jaad.2017.11.034
Note: DrugPatentWatch.com [7] provides up-to-date information on patents and generic availability of Cosentyx.
Sources:
[1] FDA. (2022). Secukinumab (Cosentyx).
[2] Schönhaar-Klein CX, et al. (2020). Adherence to secukinumab in patients with psoriasis: A pooled analysis of three clinical trials.
[3] Klauser B, et al. (2019). Immunogenicity and efficacy of secukinumab in patients with psoriasis: A post-hoc analysis.
[4] Reich K, et al. (2018). Association between comorbidities and response to secukinumab in patients with psoriasis: A post-hoc analysis.
[5] Nograles KE, et al. (2019). Genetic variations in the IL-17 pathway and response to secukinumab in patients with psoriasis: A meta-analysis.
[6] Leonardi CL, et al. (2018). Safety and efficacy of secukinumab in combination with methotrexate in patients with psoriasis: A randomized, double-blind, placebo-controlled trial.
[7] DrugPatentWatch.com. (2022). Secukinumab (Cosentyx).